---
layout: post
title: New Drug Approvals 2013 - Pt. XII - Technetium Tc 99m Tilmanocept (LymphoSeekTM)
date: '2013-08-30T17:06:00.000+01:00'
author: Simone Trubian
tags:
- 2013 New Drugs
- Diagnostic Agents
modified_time: '2013-08-30T17:06:40.324+01:00'
thumbnail: http://3.bp.blogspot.com/-9-77j27gZ4g/UiBtHbGDBhI/AAAAAAAAAyE/kd-DCSc0yNE/s72-c/full0.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4232144672896982872
blogger_orig_url: http://chembl.blogspot.com/2013/08/new-drug-approvals-2013-pt-xii.html
---

<center><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/3,0,0,1,0,0,1,0,0,1" width="400" /><br />
<br />
ATC code: <a href="http://www.whocc.no/atc_ddd_index/?code=V09IA">V09IA09</a><br />
</center><br />
<center style="text-align: left;">On March 13th 2013, the FDA approved Technetium Tc 99m Tilmanocept (LymphoSeek<sup>TM</sup>), a radioactive diagnostic agent indicated for lymphatic mapping with a hand-held <a href="http://en.wikipedia.org/wiki/Gamma_counter">gamma counter</a> to assist in the localisation of <a href="http://en.wikipedia.org/wiki/Lymph_node">lymph nodes</a> draining a primary tumour site in patients with <a href="http://en.wikipedia.org/wiki/Breast_cancer"> breast cancer</a> or <a href="http://en.wikipedia.org/wiki/Melanoma">melanoma</a>.&nbsp;</center><br />
<center style="text-align: left;">Melanoma is a malignant skin tumour, which, although rather uncommon, causes 75% of skin cancer related deaths. &nbsp;Breast cancer accounts for almost 23% of all cancers in women and in 2008 caused 13.7% of cancer related deaths in women. Lymph nodes drain lymphatic fluid coming from tissues, if the tissues contain a tumour, the node will retain cancer cells coming from it. By removing and analysing the lymph node, precious informations can be obtained regarding the spread of the tumour.<br />
<br />
Technetium Tc 99m Tilmanocept (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2108726">CHEMBL2108726</a>) acts by accumulating in lymphatic tissue and selectively binding to mannose binding receptor (<a href="http://en.wikipedia.org/wiki/Mannose_receptor">CD206</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2176854">CHEMBL2176854</a>, Uniprot:<a href="http://www.uniprot.org/uniprot/P22897">P22897</a>) found on macrophage and dendritic cells membrane. <i>In vitro</i> studies show that Technetium Tc 99m Tilmanocept binds to the human mannose binding receptor with an affinity of Kd = 2.76 x 10<sup>-11</sup> M. Clinical studies show that it accumulates in lymph nodes within 10 min and up to 30 hours after the injection.</center><br />
<center style="text-align: left;">The PDBe entry (PDBe: <a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1egg/summary">1egg</a>) for a crystal structure of the macrophage mannose receptor is shown below.<br />
</center><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://3.bp.blogspot.com/-9-77j27gZ4g/UiBtHbGDBhI/AAAAAAAAAyE/kd-DCSc0yNE/s1600/full0.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="http://3.bp.blogspot.com/-9-77j27gZ4g/UiBtHbGDBhI/AAAAAAAAAyE/kd-DCSc0yNE/s320/full0.png" width="320" /></a></div><br />
<center style="text-align: left;">Tilmanocept is a macromolecule composed of multiple units of <a href="http://en.wikipedia.org/wiki/Diethylenetriaminepentaacetic_acid">diethylenetriaminepentaacetic acid (DTPA)</a> and <a href="http://en.wikipedia.org/wiki/Mannose">mannose</a>, each covalently bonded to a 10 kDa backbone of <a href='http://en.wikipedia.org/wiki/Dextran'>dextran</a>. The DTPA acts as a <a href='http://en.wikipedia.org/wiki/Chelating_agent'>chelating agent</a> for labelling with <a href="http://en.wikipedia.org/wiki/Technetium">Technetium 99m (Tc 99m)</a>, while mannose, a naturally occurring sugar, acts as a target ligand. The active component is radioactive Tc 99m, a synthetic element widely used in nuclear medicine that decays with a half-life of 6 hours emitting Gamma-2 photons. The molecular formula of Technetium Tc 99m Tilmanocept is [C<sub>6</sub>H<sub>10</sub>O<sub>5</sub>]<sub>n</sub>.(C<sub>19</sub>H<sub>28</sub>N<sub>4</sub>O<sub>9</sub>S<sup>99m</sup>Tc)<sub>b</sub>.(C<sub>13</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>)<sub>c</sub>.(C<sub>5</sub>H<sub>11</sub>NS)<sub>a</sub>. It contains 3-8 conjugated DTPA molecules (b); 12-20 conjugated mannose molecules (c) with 0-17 amine side chains (a) remaining free. The calculated average molecular weight of Tilmanocept ranges from 15,281 to 23,454 g/mol.</center><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://2.bp.blogspot.com/-9qxtD0-EGU0/UhN5ncMFDTI/AAAAAAAAABM/b3YO52hFqMQ/s1600/Tilmanocept.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="302" src="http://2.bp.blogspot.com/-9qxtD0-EGU0/UhN5ncMFDTI/AAAAAAAAABM/b3YO52hFqMQ/s320/Tilmanocept.png" width="320" /></a></div><center style="text-align: left;"></center><br />
<center style="text-align: left;">The recommended dose of Technetium Tc 99m Tilmanocept is 18.5 MBq (0.5 mCi) as a radioactivity dose and 50 mcg as a mass dose, administered via injection at least 15 minutes prior the lymph node mapping. Technetium Tc 99m Tilmanocept has a half-life at the injection site of 1.75 to 3.05 hours.</center><center style="text-align: left;"><br />
</center><center style="text-align: left;">LymphoSeek is produced by <a href="http://www.navidea.com/">Navidea Biopharmaceuticals, Inc.</a></center>Full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202207s000lbl.pdf">here</a>.